{"id":"prednisolone-acetate-1-oph-susp","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated intraocular pressure"},{"rate":null,"effect":"Posterior subcapsular cataract formation"},{"rate":null,"effect":"Secondary ocular infection"},{"rate":null,"effect":"Ocular irritation or discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a glucocorticoid, prednisolone acetate binds to cytoplasmic glucocorticoid receptors, translocates to the nucleus, and modulates gene expression to decrease synthesis of prostaglandins, leukotrienes, and cytokines. This reduces inflammation, edema, and immune cell infiltration in ocular tissues. The acetate ester formulation enhances corneal penetration when applied topically as an ophthalmic suspension.","oneSentence":"Prednisolone acetate is a corticosteroid that suppresses inflammatory and immune responses in the eye by inhibiting phospholipase A2 and reducing production of inflammatory mediators.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:36:28.685Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory conditions of the anterior segment of the eye (conjunctivitis, keratitis, iritis, iridocyclitis)"},{"name":"Post-operative inflammation following ocular surgery"},{"name":"Allergic conjunctivitis"}]},"trialDetails":[{"nctId":"NCT04977427","phase":"PHASE4","title":"Dextenza vs Prednisolone Acetate After Cataract Surgery for Patients With Diabetes","status":"WITHDRAWN","sponsor":"Baylor Research Institute","startDate":"2021-08-31","conditions":"Cataract Diabetic, Macula Edema","enrollment":""},{"nctId":"NCT05626478","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2023-06-01","conditions":"Corneal Edema, Corneal Defect, Anterior Chamber Inflammation","enrollment":50},{"nctId":"NCT04371445","phase":"PHASE4","title":"Dextenza in the Post-op Management of Vitreoretinal Surgeries","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2020-06-01","conditions":"Vitreoretinal Surgery, Ocular Inflammation, Post-operative Pain","enrollment":30},{"nctId":"NCT04200651","phase":"PHASE4","title":"Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery","status":"TERMINATED","sponsor":"The New York Eye Surgery Center","startDate":"2020-01-13","conditions":"Glaucoma, Cataract","enrollment":25},{"nctId":"NCT04184999","phase":"PHASE4","title":"Effect of Intraoperative Dexamethasone on Post-op Dry Eye","status":"COMPLETED","sponsor":"SR Cornea Consultants","startDate":"2019-08-10","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT04521140","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2020-10-16","conditions":"Corneal Edema, Corneal Defect, Corneal Transplant","enrollment":36},{"nctId":"NCT04479748","phase":"PHASE4","title":"DEXTENZA Compared to Topical Steroid Therapy Prior to Cataract Surgery in Patients Who Receive Premium Intraocular Lenses","status":"COMPLETED","sponsor":"Prism Vision Group","startDate":"2020-10-01","conditions":"Cataract","enrollment":13},{"nctId":"NCT03578276","phase":"PHASE4","title":"Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen","status":"COMPLETED","sponsor":"Carolina Eyecare Physicians, LLC","startDate":"2018-06-22","conditions":"Cataract","enrollment":35},{"nctId":"NCT04590183","phase":"NA","title":"The Effectiveness and Safety of FK-506 for the Treatment of Posner-Schlossman Syndrome","status":"UNKNOWN","sponsor":"Peking University","startDate":"2020-10-01","conditions":"Posner Schlossman Syndrome","enrollment":30},{"nctId":"NCT03123614","phase":"PHASE4","title":"Loteprednol vs. Prednisolone and Fluorometholone","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-19","conditions":"Intraocular Pressure, Corneal Opacity","enrollment":131},{"nctId":"NCT01437982","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-08-05","conditions":"Conjunctivitis, Seasonal Allergic, Conjunctivitis, Giant Papillary, Inflammation","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PRED FORTE®, OMNIPRED®","Prednisolone Acetate","Omnipred, Pred Forte"],"phase":"marketed","status":"active","brandName":"Prednisolone Acetate 1% Oph Susp","genericName":"Prednisolone Acetate 1% Oph Susp","companyName":"SR Cornea Consultants","companyId":"sr-cornea-consultants","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prednisolone acetate is a corticosteroid that suppresses inflammatory and immune responses in the eye by inhibiting phospholipase A2 and reducing production of inflammatory mediators. Used for Inflammatory conditions of the anterior segment of the eye (conjunctivitis, keratitis, iritis, iridocyclitis), Post-operative inflammation following ocular surgery, Allergic conjunctivitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":7,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}